Table 1 Alemtuzumab treatment for T-cell... | American Society of Hematology

Table 1

Alemtuzumab treatment for T-cell prolymphocytic leukemia at the Royal Marsden Hospital: patient characteristics and treatment outcomes

Alemtuzumab treatment	No. of cases	Sex, male/female	Median age, (range)	No. (%) with extramedullary disease*	ORR, no. (%)	CR rate, no. (%)	PFS at 12 mo,† %	Given SCT, %	OS at 48 mo, %
Intravenous at first-line	32	22:10	62 (36-85)	10/24 (42)	29/32 (91)	26/32 (81)	67	50	37
Subcutaneous at first-line	9	6:3	61 (36-79)	4/9 (44)	3/9 (33)	3/9 (33)	67	55	33
Intravenous as subsequent therapy‡	45	34:11	59 (35-81)	15/26 (58)	31/42 (74)	25/42 (60)	26	30	18

Alemtuzumab treatment	No. of cases	Sex, male/female	Median age, (range)	No. (%) with extramedullary disease*	ORR, no. (%)	CR rate, no. (%)	PFS at 12 mo,† %	Given SCT, %	OS at 48 mo, %
Intravenous at first-line	32	22:10	62 (36-85)	10/24 (42)	29/32 (91)	26/32 (81)	67	50	37
Subcutaneous at first-line	9	6:3	61 (36-79)	4/9 (44)	3/9 (33)	3/9 (33)	67	55	33
Intravenous as subsequent therapy‡	45	34:11	59 (35-81)	15/26 (58)	31/42 (74)	25/42 (60)	26	30	18

Including skin, liver, central nervous system, ascites, tonsils, larynx, and pleural effusions.

Including SCT where applicable.

After prior pentostatin (n = 32) or other treatment, including cladribine, fludarabine, cyclophosphamide, chlorambucil, and CHOP (n = 13).